

CHANGE TO PROJECT STATUS

Project # 1089



Project has been placed on hold.

Reason: _____

No further work is being done.

Some additional tasks are being done, which will be completed _____.

Work is expected to resume _____.

If longer than 3 weeks:
(Variance) report attached (or to follow) describing work completed to date.

Finance: Calculate earned fees and invoice as necessary.

Project has been cancelled.

Reason: Poor data outcome - client cancelled
project

(Variance) report attached (or to follow) describing work completed to date.

Finance: Calculate earned fees and invoice as necessary.

Distribution: File, John, Mark, Sharon, Marion, Monica, Mary,
Barbara, Erin, Una, _____



Laden, Sally

From: Laden, Sally
Sent: Thursday, December 14, 2000 10:13 AM
To: Romankiewicz, John; Phillips, Marlon; Kistner, Una; Holody, Mark; Blivins, Sharon
Subject: Cancellation of project 1059

Yes Virginia, there is a God.

SB cancelled our project 1059 (long-term panic disorder study). Reason: the side effect data analysis was terribly unfavorable to our favorite antidepressant. And we hate when that happens! Also there are some issues with the lead author, so they took the path of least resistance.

I am saving Mark's end of year forms to do early next week (I'll have them ready on deadline), and will incorporate this news into the 1059 report.

Also, I'll go through the file and complete a cancellation/variance report to close this project out once and for all.

Thanks, and please contact me if you have questions.
Sally

—Original Message—

From: Laden, Sally
Sent: Thursday, December 14, 2000 10:04 AM
To: 'Daniel_B_Burnham@sbphrd.com'
Cc: Martin_X_Steiner@sbphrd.com; Rosemary_Oakes@sbphrd.com
Subject: RE: PAR 222 manuscript

Thank you Dan, Marty, and Rosemary.

We understand your reasons for cancelling this project. There are some data that no amount of spin will fix, and these certainly fall into this category.

We will close out our books and conduct a final reconciliation. One last question: Is Jim aware of your decision? Should we contact him? Please advise.

Good luck with the merger and we hope to work with you again.


Sally

—Original Message—

From: Daniel_B_Burnham@sbphrd.com [mailto:Daniel_B_Burnham@sbphrd.com]
Sent: Tuesday, December 12, 2000 11:53 AM
To: Laden, Sally
Cc: Martin_X_Steiner@sbphrd.com; Rosemary_Oakes@sbphrd.com
Subject: RE: PAR 222 manuscript

Sally, to catch you up on the above manuscript, the issue of discontinuation vs relapse is obviously a concern of the J Clin Psychiatry reviewers and unfortunately we feel it cannot be adequately addressed by the additional AE information in Tables 7 and 8 (we are aware that Jim Bailenger feels otherwise about this information). As I have stated previously, this information is largely inconclusive. Furthermore, attention on paroxetine d/c symptoms continues to be an issue in the medical community. Thus, we have decided to terminate further work on this manuscript. Thank-you for your long-standing efforts on this manuscript. Hopefully, we can work together again in the new GSK organization.

regards-Dan (tel 610 917-6471)



Laden, Sally

From: Daniel_B_Burnham@sbphrd.com
Sent: Friday, December 15, 2000 10:28 AM
To: BALLENGJ@musc.edu
Cc: Laden, Sally; Martin_X_Steiner@sbphrd.com; Rosemary_Oakes@sbphrd.com
Subject: SB position on paroxetine longterm panic disorder study 222 manuscript

Jim, to catch you up on the above manuscript, the issue of discontinuation sx vs relapse is a central concern of the J Clin Psychiatry reviewers and unfortunately Marty and I feel it cannot be adequately addressed by the additional AE information in Tables 7 and 8. As I have stated previously, this information is largely inconclusive. Furthermore, attention on paroxetine d/c symptoms continues to be an issue in the medical community. Thus, we propose that further work on this manuscript be terminated. I am aware that you have a different take on this issue and understand if you want to discuss it further. Please email or call me back if you would like to telecon with Marty and I in January. In any case, Marty, Rosemary, Sally Laden and I greatly appreciate the help and leadership you have provided in drafting this manuscript. Regards and best wishes for the holiday season-Dan (tel 610 917 6471).

Laden, Sally

From: Daniel_B_Burnham@sbphrd.com
Sent: Friday, December 15, 2000 10:12 AM
To: Laden, Sally
Cc: Martin_X_Steiner@sbphrd.com; Rosemary_Oakes@sbphrd.com
Subject: RE: PAR 222 manuscript

Sally, I called Jim's # at USC (843 792 0028) and he will be starting a part-time sabbatical leave in January 2001. I will inform him by separate email of SB's position on the manuscript and invite him to call me when he returns from ACNP and holiday on Dec 29 or in January.

Regards-Dan

CHANGE TO PROJECT STATUS

Project # 1069

Project has been placed on hold.

Reason: _____

No further work is being done.

Some additional tasks are being done, which will be completed _____.

Work is expected to resume _____.

If longer than 3 weeks:

(Variance) report attached (or to follow) describing work completed to date.

Finance: Calculate earned fees and invoice as necessary.

Project has been cancelled.

Reason: Poor data outcome - client cancelled
project

(Variance) report attached (or to follow) describing work completed to date.

Finance: Calculate earned fees and invoice as necessary.

Distribution: File, John, Mark, Sharon, Marion, Monica, Mary,

Barbara, Erin, Una, _____

Laden, Sally

From: Laden, Sally
Sent: Thursday, December 14, 2000 10:13 AM
To: Romankiewicz, John; Phillips, Marion; Kistner, Una; Holody, Mark; Blvins, Sharon
Subject: Cancellation of project 1059

Yes Virginia, there is a God.

SB cancelled our project 1059 (long-term panic disorder study). Reason: the side effect data analysis was terribly unfavorable to our favorite antidepressant. And we hate when that happens! Also there are some issues with the lead author, so they took the path of least resistance.

I am saving Mark's end of year forms to do early next week (I'll have them ready on deadline), and will incorporate this news into the 1059 report.
Also, I'll go through the file and complete a cancellation/variance report to close this project out once and for all.

Thanks, and please contact me if you have questions.
Sally

—Original Message—

From: Laden, Sally
Sent: Thursday, December 14, 2000 10:04 AM
To: 'Daniel_B_Burnham@sbphrd.com'
Cc: Martin_X_Steiner@sbphrd.com; Rosemary_Oakes@sbphrd.com
Subject: RE: PAR 222 manuscript

Thank you Dan, Marty, and Rosemary.

We understand your reasons for cancelling this project. There are some data that no amount of spin will fix, and these certainly fall into this category.

We will close out our books and conduct a final reconciliation. One last question: Is Jim aware of your decision? Should we contact him? Please advise.


Good luck with the merger and we hope to work with you again.

Sally

—Original Message—

From: Daniel_B_Burnham@sbphrd.com [mailto:Daniel_B_Burnham@sbphrd.com]
Sent: Tuesday, December 12, 2000 11:53 AM
To: Laden, Sally
Cc: Martin_X_Steiner@sbphrd.com; Rosemary_Oakes@sbphrd.com
Subject: RE: PAR 222 manuscript

Sally, to catch you up on the above manuscript, the issue of discontinuation vs relapse is obviously a concern of the J Clin Psychiatry reviewers and unfortunately we feel it cannot be adequately addressed by the additional AE information in Tables 7 and 8 (we are aware that Jim Ballenger feels otherwise about this information). As I have stated previously, this information is largely inconclusive. Furthermore, attention on paroxetine d/c symptoms continues to be an issue in the medical community. Thus, we have decided to terminate further work on this manuscript. Thank-you for your long-standing efforts on this manuscript. Hopefully, we can work together again in the new GSK organization.



regards-Dan (tel 810 917-6471)



Laden, Sally

From: Daniel_B_Burnham@sbphrd.com
Sent: Friday, December 15, 2000 10:26 AM
To: BALLENGJ@musc.edu
Cc: Laden, Sally; Martin_X_Steiner@sbphrd.com; Rosemary_Oakes@sbphrd.com
Subject: SB position on paroxetine longterm panic disorder study 222 manuscript

Jim, to catch you up on the above manuscript, the issue of discontinuation sx vs relapse is a central concern of the J Clin Psychiatry reviewers and unfortunately Marty and I feel it cannot be adequately addressed by the additional AE information in Tables 7 and 8. As I have stated previously, this information is largely inconclusive. Furthermore, attention on paroxetine d/c symptoms continues to be an issue in the medical community. Thus, we propose that further work on this manuscript be terminated. I am aware that you have a different take on this issue and understand if you want to discuss it further. Please email or call me back if you would like to telecon with Marty and I in January. In any case, Marty, Rosemary, Sally Laden and I greatly appreciate the help and leadership you have provided in drafting this manuscript. Regards and best wishes for the holiday season-Dan (tel 610 917 6471).

Laden, Sally

From: Daniel_B_Burnham@sbphrd.com
Sent: Friday, December 15, 2000 10:12 AM
To: Laden, Sally
Cc: Martin_X_Steiner@sbphrd.com; Rosemary_Oakes@sbphrd.com
Subject: RE: PAR 222 manuscript

Sally, I called Jim's # at USC (843 792 0028) and he will be starting a part-time sabbatical leave in January 2001. I will inform him by separate email of SB's position on the manuscript and invite him to call me when he returns from ACNP and holiday on Dec 29 or in January.

Regards-Dan